Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism

European Journal of Endocrinology

Volumn 134, Issue 3, 1996, Pages 320-325

  Valdemarsson, Stig ^a   Leckström, Arnold ^b   Westermark, Per ^b   Bergenfelz, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLYCOPROTEIN; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL;

EID: 0029993744     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1340320     Document Type: Article

References (31)

1. Kim H, Kalkhoff RK, Costrini NV, Cerletty JM, Jacobsen M. Plasma insulin disturbances in primary hyperparathyroidism. J Clin Invest 1971;50:2596-605
2. Ljunghall S, Palmér M, Åkerström G, Wide L. Diabetes mellitus, glucose tolerance and insulin response in primary hyperparathyroidism. Eur J Clin Invest 1983;12:373-7
3. Taylor WH. The prevalence of diabetes mellitus in patients with primary hyperparathyroidism and their relatives. Diabet Med 1991;8:683-7
4. Kautsky-Willer A, Pacini G, Niederle B, Schernthaner G, Prager R. Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. Clin Endocrinol 1992;37:147-55
5. Kumar S, Olukoga AO, Gordon C, Mawer EB, France M, Hosker JP, et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994;40:47-53
6. Westermark P, Johnson KH, O'Brien TD, Betsholtz C. Islet amyloid polypeptide - a novel controversy in diabetes research. Diabetologia 1992;35:297-303
7. Zaidi M, Shankar VS, Haung CLH, Pazianas M, Bloom S. Amylin in bone conservation. Current evidence and hypothetical considerations. Trends Endocrinol Metabol 1993;4:255-9
8. Datta HK, Zaidi M, Wimalawansa SJ. In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochem Biophys Res Commun 1989;162:876-81
9. Mayer E, Kadowaki S, Williams G, Neoman AW. Mode of action of 1.25-dihydroxyvitamin D3. In: Kumar R, editor. Vitamin D: basic and clinical aspects. The Hague: Martinus Nijhoff, 1984:25-30
10. Christmanson L, Betsholtz C, Leckström A. Engström U, Cortie C, Johnson KH, et al. Islet amyloid polypeptide in the rabbit and European hare: studies on its relationship to amyloidogenesis. Diabetologia 1993;36:183-8
11. Thorell JI, Larsson SM. Radioimmunoassay and related techniques. St Louis: CV Mosby Company, 1978:205-11
12. Duh QY, Arnaud CD, Levin KE, Clark OH. Parathyroid hormone: Before and after parathyroidectomy. Surgery 1986;100:1021-30
13. Fürnsinn C, Leuvenink H, Roden M, Nowotny P, Schneider B, Rohac M, et al. Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am J Physiol 1994;267:E 300-5
14. Fürnsinn C, Nowotny P, Roden M, Rohac M, Pieber T, Parzer S, et al. Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcemia and fades during long-term exposure. Acta Endocrinol 1993;129:360-5
15. Young AA, Gedulin B, Gaeta LS, Prickett KSK, Larson E, Rink TJ. Selective amylin antagonist suppresses rise in plasma lactate after intravenous glucose in rats. Evidence for a metabolic role of endogenous amylin. FEBS Lett 1994;342:237-41
16. Sowa R, Sanke T, Hirayama J. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 1990;33:118-20
17. Leighton B, Cooper GJS. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988;335:632-5
18. Blackard WG, Core JN, Kellum JM. Amylin/insulin secretory ratios in morbidly obese man: inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994;78:1257-60
19. Kautsky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, et al. Role of islet amyloid polypeptide secretion in insulin resistant humans. Diabetologia 1994;37:188-94
20. Wilding JP, Khandan-Nia N, Bennet WM, Gilbey SG, Beacham J, Ghatei MA, et al. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994;37:166-9
21. Kautsky-Willer A, Niederle B, Schernthaner G, Prager R. Diabetes mellitus and carbohydrate metabolism in primary hyperparathyroidism. Wien Klin Wochenschr 1993;105:158-62
22. Yasuda K, Hurukawa Y, Okuyama M, Kikuchi M, Yoshinaga K. Glucose tolerance and insulin secretion in patients with parathyroid disorders. Effect of serum calcium on insulin release. N Eng J Med 1975;292:501-4
23. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986; 29:142-54
24. DeFronzo RA, Lang R. Hypophosphatemia and glucose tolerance. Evidence for tissue insensitivity to insulin. N Eng J Med 1980;303:1259-63
25. Fadda GZ, Akmal M, Lipson LG, Massry SG. Direct effect of parathyroid hormone on insulin secretion from pancreatic islets. Am J Physiol 1990;258:E975-84
26. Parna AF, Fadda GZ, Zhou XJ, Massry SG. Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am J Physiol 1990;259:F210-6
27. Prager R, Schernthaner G, Kovarik J, Cichini G, Klauhofer K, Wilvonseder R. Primary hyperparathyroidism is associated with decreased receptor binding and glucose intolerance. Calcif Tissue Int 1984;36:253-8
28. DeFronzo RA, Andre R, Edgar P, Walker WG. Carbohydrate metabolism in uremia: a review. Medicine (Baltimore) 1973;52: 469-81
29. Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, DeFronzo RA. Role of parathyroid hormone in glucose intolerance in chronic renal failure. J Clin Invest 1985;75:1037-44
30. Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med 1994;121:745-9
31. Bone HG, Zerwekh JE, Haussler MR, Pak CYC. Effect of parathyroidectomy on serum 1,2 5-dihydroxyvitamin D and intestinal calcium absorption in primary hyperparathyroidism. J Clin Endocrinol Metab 1979;48:877-9